1.Define the ADME processes and discuss their role in drug metabolism

1.Define the ADME processes and discuss their role in drug metabolism 2.Explain Bioavailability and bioequivalence 3.Explain the role of the cytochrome P450 enzyme system in drug metabolism. 4.Explain the concept of lead compound and its applications in drug discovery. 5.Explain the role of structure-based drug design in drug discovery 6.Define pharmacogenomics and explain its relevance in personalized medicine. 7.Describe the regulatory requirements involved in the drug approval process 8.What are pharmacogenomic biomarkers and how are they used in clinical practice 9.Explain how pharmacogenomic testing can optimize drug therapy. 10.What are Phase I reactions in drug metabolism? Provide examples of each.

Reading File

This is a broad pharmacology and drug-discovery set. It covers:

Pharmacokinetics and drug metabolism
- ADME
- Bioavailability and bioequivalence
- Phase I reactions
- Cytochrome P450 system
Drug discovery
- Lead compounds
- Structure-based drug design
Pharmacogenomics and personalized medicine
- Definition and clinical relevance
- Pharmacogenomic biomarkers
- Optimizing therapy through genetic testing
Drug regulation
- Preclinical studies, clinical trial phases, regulatory review, approval, and post-marketing surveillance

At a high level, ADME explains what the body does to a medicine, while pharmacogenomics explains why people can respond differently to the same dose. Drug discovery identifies and optimizes molecules likely to be effective and safe, then regulatory systems require evidence of quality, safety, and efficacy before marketing approval.

Which section would you like as detailed study notes first: 1, 2, 3, or 4?

Provide detailed answers to all 10 questions

Reading File

Finding Sources

Searching PubMed

pharmacogenomics AND implementation

Searching the Web

FDA drug development process IND NDA BLA pharmacogenomic biomarkers table labeling

Reading File

Reading Web Page

https://www.fda.gov/media/122407/download

1. ADME processes and their role in drug metabolism

ADME describes the journey of a drug through the body:

Process	Meaning	Main determinants	Clinical importance
A - Absorption	Movement of drug from the administration site into systemic circulation	Route, formulation, lipid solubility, pH/pKa, surface area, blood flow, food, first-pass metabolism	Determines onset and amount of drug reaching blood
D - Distribution	Reversible movement of drug from blood to tissues and sites of action	Blood flow, capillary permeability, plasma-protein binding, tissue binding, lipid solubility	Determines tissue concentrations, apparent volume of distribution, and duration
M - Metabolism	Enzymatic chemical conversion of drug to metabolites	Liver function, enzyme activity, genetic variation, age, drug interactions	Usually converts lipid-soluble drugs to more polar compounds for elimination; can inactivate, activate, or toxify drugs
E - Excretion	Irreversible removal of drug or metabolite from the body	Renal function, biliary secretion, urine pH, pulmonary elimination	Determines clearance, half-life, dose interval, and risk of accumulation

A. Absorption

Absorption is especially relevant for oral medicines. A drug must dissolve, cross gastrointestinal membranes, and enter portal blood. Before reaching systemic circulation, it may be metabolized in the intestinal wall and liver. This is called first-pass metabolism or presystemic elimination.

For example, nitroglycerin undergoes extensive hepatic first-pass metabolism and is therefore commonly given sublingually or transdermally rather than swallowed.

B. Distribution

After entering blood, the drug distributes into extracellular fluid, tissues, and sometimes fat or bone. Only unbound (free) drug generally crosses membranes, binds receptors, is filtered at the kidney, and is available for metabolism.

A highly albumin-bound drug may have less immediately active free drug. Changes in albumin concentration, renal failure, liver disease, or displacement by another highly protein-bound drug can alter free concentrations.

C. Metabolism

Metabolism, also called biotransformation, occurs mainly in the liver but also in the gut wall, kidney, lung, plasma, and other tissues. It usually makes a drug more water-soluble so that renal or biliary excretion is easier.

Metabolism can produce:

Inactive metabolites, such as oxidation of many drugs before elimination.
Active metabolites, such as codeine conversion to morphine by CYP2D6.
Toxic metabolites, such as formation of N-acetyl-p-benzoquinone imine (NAPQI) from paracetamol/acetaminophen.
Active drug from a prodrug, such as enalapril to enalaprilat.

Most metabolic reactions are classified as Phase I or Phase II. They do not have to occur in sequence.

D. Excretion

The kidney is the main excretory organ for many drugs and metabolites. Renal elimination may occur by:

Glomerular filtration of unbound drug
Active tubular secretion
Tubular reabsorption, which is influenced by lipid solubility and urine pH

Other routes include bile and feces, expired air for volatile substances, sweat, saliva, and breast milk.

Overall role of ADME

ADME determines the drug concentration at its target site over time. It therefore determines:

Dose and dosing interval
Route of administration
Time to onset and duration of action
Need for dose adjustment in renal or hepatic disease
Interpatient variability
Drug-drug interactions
Risk of toxicity or therapeutic failure

Drug elimination includes both metabolism and excretion. Metabolism commonly increases polarity, thereby facilitating excretion. Lippincott Illustrated Reviews: Pharmacology, pp. 52-53.

2. Bioavailability and bioequivalence

Bioavailability

Bioavailability (F) is the fraction of an administered dose of unchanged drug that reaches the systemic circulation.

For an intravenous dose, bioavailability is conventionally 100%, because the drug is delivered directly into systemic circulation.

For oral and other extravascular routes, bioavailability may be less than 100% because of:

Incomplete absorption
Degradation in the gastrointestinal tract
Poor dissolution of the dosage form
Metabolism in the gut wall
Hepatic first-pass metabolism
Food effects
Drug interactions affecting transporters or enzymes

Formula

Absolute bioavailability is commonly estimated by comparing area under the plasma concentration-time curve (AUC):

[ F = \frac{AUC_{oral}}{AUC_{IV}} \times \frac{Dose_{IV}}{Dose_{oral}} ]

AUC reflects total systemic exposure to a drug.

Example

If 100 mg is taken orally but only 50 mg reaches systemic circulation as unchanged drug, oral bioavailability is 50%, or F = 0.5.

Factors that affect bioavailability

Dosage form: solution, tablet, capsule, sustained-release form
Particle size and dissolution rate
Gastric emptying and intestinal motility
Food and gastric pH
Intestinal or hepatic first-pass metabolism
P-glycoprotein and other drug transporters
Liver disease or reduced hepatic blood flow
Drug interactions

Bioequivalence

Bioequivalence means that two pharmaceutically equivalent products have no clinically meaningful difference in the rate and extent of absorption of the active ingredient when used under comparable conditions.

Pharmaceutical equivalents contain:

The same active ingredient
The same strength or concentration
The same dosage form
The same route of administration

Bioequivalence is usually evaluated by comparing pharmacokinetic measures, especially:

AUC: total extent of systemic exposure
Cmax: peak plasma concentration
Tmax: time to reach peak concentration, usually supportive rather than the principal regulatory endpoint

In standard crossover bioequivalence studies, the test product is compared with a reference product in the same volunteers. Regulatory assessment commonly uses the 90% confidence interval for the ratio of test to reference geometric means for AUC and Cmax. For most conventional products, this interval is expected to lie within 80.00% to 125.00%.

Importance

Bioequivalence supports approval of generic medicines without requiring full repetition of large efficacy trials. It helps ensure that an approved generic product will provide systemic exposure comparable to the reference product when substituted appropriately.

However, some products require special consideration because small exposure differences may be clinically important, for example:

Narrow therapeutic-index drugs
Modified-release products
Locally acting products
Inhaled medicines
Complex biologics, which follow a distinct biosimilar regulatory pathway

The textbook definition states that pharmaceutical equivalents are bioequivalent when the rate and extent of availability are not significantly different under suitable, identical test conditions. Goodman & Gilman's The Pharmacological Basis of Therapeutics, p. 53.

3. Role of the cytochrome P450 enzyme system in drug metabolism

The cytochrome P450 (CYP) system is a superfamily of heme-containing enzymes that catalyze oxidative metabolism of many drugs and endogenous compounds. CYP enzymes are located mainly in the smooth endoplasmic reticulum of hepatocytes, although they are also present in intestinal mucosa and other tissues.

Main roles

Phase I metabolism
CYP enzymes carry out oxidation reactions that introduce or expose functional groups, such as -OH, -NH₂, or -SH.
Drug inactivation
Many drugs are converted into less active or inactive metabolites.
Prodrug activation
Some drugs require CYP metabolism to become active.
Example: codeine is partly converted to morphine by CYP2D6.
Formation of toxic metabolites
CYP metabolism can occasionally produce reactive intermediates.
Example: acetaminophen is partly converted by CYP enzymes, especially CYP2E1, to NAPQI, a hepatotoxic metabolite normally detoxified by glutathione.
Endogenous metabolism
CYP enzymes also metabolize steroid hormones, fatty acids, bile acids, vitamin D-related compounds, and other endogenous molecules.

Important CYP isoenzymes

Enzyme	Examples of substrates or clinical roles
CYP3A4/5	Metabolizes a large proportion of commonly used drugs, including many statins, calcium-channel blockers, immunosuppressants, benzodiazepines, and some antivirals
CYP2D6	Codeine, tramadol, many antidepressants, antipsychotics, beta-blockers
CYP2C9	Warfarin, phenytoin, several NSAIDs
CYP2C19	Clopidogrel activation, proton-pump inhibitors, some antidepressants
CYP1A2	Caffeine, theophylline, clozapine
CYP2E1	Ethanol-related metabolism and acetaminophen toxic-metabolite formation

Enzyme inhibition

A CYP inhibitor reduces enzyme activity. This can increase the concentration of a drug normally cleared by that enzyme, increasing adverse-effect risk.

Examples:

Clarithromycin, ketoconazole, ritonavir, and grapefruit juice can inhibit CYP3A activity.
Fluoxetine and paroxetine can inhibit CYP2D6.
Fluconazole can inhibit CYP2C9 or CYP2C19.

Example: a patient receiving simvastatin plus a potent CYP3A inhibitor may develop markedly increased statin exposure and risk of myopathy or rhabdomyolysis.

Enzyme induction

An inducer increases enzyme expression or activity, usually after days to weeks. This can lower concentrations of drugs metabolized by that pathway and cause therapeutic failure.

Examples:

Rifampicin/rifampin
Carbamazepine
Phenytoin
Phenobarbital
St John's wort

Example: rifampicin can increase metabolism of oral contraceptives, reducing contraceptive effectiveness.

Genetic variation

CYP genes are polymorphic. A person may be classified as a poor, intermediate, normal, rapid, or ultrarapid metabolizer, depending on the gene and variants present.

Examples:

CYP2D6 poor metabolizers may obtain little analgesia from codeine because they form less morphine.
CYP2D6 ultrarapid metabolizers may form excessive morphine from codeine and develop toxicity.
CYP2C19 loss-of-function variants can reduce activation of clopidogrel and reduce antiplatelet response.

Thus, CYP activity varies because of genetics, age, liver disease, diet, smoking, concomitant medicines, and inflammation. CYP-mediated drug interactions are among the most important causes of clinically relevant changes in drug exposure. Lippincott Illustrated Reviews: Pharmacology, pp. 54-56.

4. Lead compound and its applications in drug discovery

A lead compound is a chemical entity with reproducible, promising biological activity against a selected therapeutic target and sufficient potential to be optimized into a drug candidate.

A lead is not usually ready for clinical use. It is a starting point for systematic chemical modification and testing.

Characteristics of a useful lead compound

A good lead generally has:

Measurable activity against the intended target
Adequate potency and selectivity
A reproducible structure-activity relationship
Chemical tractability, meaning it can be synthesized and modified
Early evidence of acceptable absorption, distribution, metabolism, excretion, and toxicity properties
Potential for intellectual-property protection

Sources of lead compounds

Natural products
Examples include paclitaxel from yew trees and artemisinin from Artemisia annua.
High-throughput screening
Large chemical libraries are screened against a biological target.
Fragment-based screening
Small, low-molecular-weight fragments that bind weakly are identified and then grown or linked into more potent molecules.
Virtual screening
Computational methods screen compound libraries against a target or pharmacophore.
Existing drugs and repurposing
An established medicine may become a lead for a new indication.
Rational design based on endogenous ligands
Natural substrates, hormones, neurotransmitters, or receptor ligands can inspire analogues.

Lead optimization

Once a lead is identified, medicinal chemists modify its structure to improve properties. This process is lead optimization.

Goals include:

Increasing potency
Improving target selectivity
Reducing off-target toxicity
Improving oral bioavailability
Reducing rapid metabolism
Avoiding reactive metabolites
Increasing half-life where appropriate
Improving solubility and formulation properties
Reducing interactions with CYP enzymes, transporters, or hERG cardiac ion channels

Structure-activity relationship

A structure-activity relationship (SAR) links specific chemical changes to changes in biological activity. For example, replacement of a functional group may improve receptor binding, reduce metabolism, or decrease toxicity.

Applications

Lead compounds are used to:

Establish whether a target is druggable
Validate a biological mechanism
Generate optimized analogues
Identify a preclinical candidate
Develop chemical probes for laboratory research
Support patent development and translational research

A lead compound therefore bridges initial target discovery and selection of a clinical drug candidate.

5. Role of structure-based drug design in drug discovery

Structure-based drug design (SBDD) is the design or optimization of drug molecules using knowledge of the three-dimensional structure of a biological target, usually a protein such as an enzyme, receptor, ion channel, or viral protein.

The target structure may be obtained by:

X-ray crystallography
Cryo-electron microscopy
Nuclear magnetic resonance spectroscopy
Homology modeling or computational prediction when an experimental structure is unavailable

Basic principle

A drug acts by binding to a target. If the target's three-dimensional binding site is known, scientists can design molecules that fit the site and make favorable interactions, such as:

Hydrogen bonds
Ionic interactions
Hydrophobic interactions
van der Waals interactions
Covalent interactions, for selected targets

Main steps

Identify and validate a disease-relevant molecular target.
Determine or model its three-dimensional structure.
Identify a binding pocket or allosteric site.
Screen fragments or virtual compound libraries computationally.
Select chemical hits predicted to bind well.
Confirm activity experimentally.
Optimize molecules through iterative design, synthesis, structural testing, and biological testing.
Assess selectivity, pharmacokinetics, toxicity, and resistance potential.

Approaches

A. Structure-based virtual screening

Large compound libraries are docked computationally into a target binding site. Compounds are ranked by predicted binding orientation and affinity, then tested experimentally.

B. Fragment-based drug design

Very small molecules are screened for weak binding. Structural data show exactly how fragments bind. Fragments can then be expanded, linked, or merged to make potent lead compounds.

C. De novo design

A molecule is designed from scratch to occupy specific regions of a binding pocket.

D. Structure-guided lead optimization

Structural information explains why a lead binds and guides modifications to improve potency, selectivity, solubility, or metabolic stability.

Examples

HIV protease inhibitors were designed using structural knowledge of the viral protease active site.
Imatinib was developed to selectively inhibit the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Many modern kinase inhibitors use structural knowledge to distinguish active and inactive kinase conformations.
SARS-CoV-2 main protease inhibitors, including nirmatrelvir, were developed using protease structural information.

Advantages

Can shorten hit discovery and optimization
Allows rational targeting of specific binding-site features
Can improve selectivity and reduce off-target activity
Helps anticipate resistance mutations
Is useful even when high-throughput screening is impractical
Supports design of inhibitors for difficult targets

Limitations

Protein structures may be incomplete or represent only one conformation.
Proteins are dynamic, whereas many models are static.
Docking scores are approximations, not direct proof of activity.
Cell permeability, metabolism, toxicity, and clinical efficacy cannot be predicted reliably from binding alone.
Experimental pharmacology and clinical testing remain essential.

SBDD is therefore a tool for more informed discovery, not a replacement for laboratory validation or clinical trials.

6. Pharmacogenomics and its relevance in personalized medicine

Pharmacogenomics is the study of how variations across a person's genome influence response to medicines. It includes genetic effects on pharmacokinetics, pharmacodynamics, drug efficacy, and adverse drug reactions.

Pharmacogenetics often refers to the effect of one or a few genes on response to a drug, whereas pharmacogenomics is the broader genome-wide concept. In clinical usage, the terms are sometimes used interchangeably.

Why it matters

The same drug and standard dose can cause:

Excellent therapeutic benefit in one person
No useful response in another
Serious toxicity in a third person

Genetic variation may affect:

Drug-metabolizing enzymes
Example: CYP2D6, CYP2C19, CYP2C9.
Drug transporters
Example: SLCO1B1, which affects hepatic uptake of several statins.
Drug targets
Example: tumor mutations in EGFR, BRAF, HER2, or KRAS can determine whether a targeted cancer therapy is appropriate.
Immune-response genes
Example: HLA alleles associated with severe immune-mediated adverse drug reactions.

Relevance in personalized medicine

Personalized medicine aims to select the most appropriate treatment for an individual rather than treating all patients as biologically identical. Pharmacogenomics contributes by helping clinicians select:

The most suitable medicine
The starting dose
Whether dose escalation or reduction is appropriate
Whether a medicine should be avoided
Whether enhanced monitoring is needed

Key examples

Gene or marker	Drug	Clinical use
*HLA-B57:01**	Abacavir	Avoid abacavir in positive patients due to major hypersensitivity risk
*HLA-B15:02**	Carbamazepine, oxcarbazepine	Helps prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in relevant populations
TPMT, NUDT15	Thiopurines	Guides dose reduction or alternative treatment to reduce severe myelosuppression
CYP2C19	Clopidogrel	Loss-of-function variants may support use of an alternative antiplatelet drug in relevant clinical settings
CYP2D6	Codeine, tramadol	Identifies patients at risk of inadequate effect or excessive opioid exposure
SLCO1B1	Simvastatin	Identifies elevated risk of statin-associated muscle toxicity
DPYD	Fluoropyrimidines	Guides dosing or avoidance to reduce severe toxicity
EGFR, ALK, HER2, BRAF, KRAS	Targeted anticancer drugs	Helps match therapy to tumor biology

Pharmacogenomics does not replace clinical assessment. Renal function, liver function, age, pregnancy, drug interactions, comorbidities, adherence, and environmental factors remain important.

Pharmacogenomics examines genetic variation affecting drug response and is a component of precision medicine. Lippincott Illustrated Reviews: Pharmacology, p. 1578.

7. Regulatory requirements involved in the drug approval process

Drug approval is intended to establish that a product has suitable quality, safety, and efficacy for its intended use. Exact requirements differ across jurisdictions, but the following describes the usual U.S. pathway under the Food and Drug Administration framework.

1. Discovery and preclinical development

Before human testing, the sponsor conducts laboratory and animal studies to define:

Pharmacology and mechanism of action
Pharmacokinetics and metabolism
Acute and repeated-dose toxicity
Genotoxicity
Reproductive and developmental toxicity, where appropriate
Carcinogenicity for drugs intended for long-term use, where appropriate
Safety pharmacology, including cardiovascular, respiratory, and central nervous-system risks
Chemistry, manufacturing, and controls (CMC), including identity, purity, stability, formulation, and manufacturing methods

Studies supporting clinical development should generally comply with Good Laboratory Practice (GLP) requirements where applicable.

2. Investigational New Drug application

Before initiating a U.S. clinical trial, a sponsor typically submits an Investigational New Drug (IND) application.

An IND includes:

Preclinical pharmacology and toxicology data
Manufacturing and quality information
The clinical protocol
Investigator information
Plans for monitoring safety
Institutional review board approval and informed-consent procedures

The IND must provide a reasonable basis for concluding that initial human exposure is justified.

3. Clinical trials

Clinical trials should comply with Good Clinical Practice (GCP), ethical review requirements, protocol adherence, informed consent, data integrity requirements, and safety reporting obligations.

Phase	Main participants and aim
Phase I	Usually small numbers of healthy volunteers, though often patients in oncology. Assesses safety, tolerability, pharmacokinetics, pharmacodynamics, and dose range.
Phase II	Patients with the target condition. Explores preliminary efficacy, dose-response relationship, and short-term safety.
Phase III	Large patient populations. Confirms efficacy, characterizes safety, compares treatment with placebo or standard care when appropriate, and supports labeling.
Phase IV	Post-marketing studies. Further evaluate rare adverse effects, long-term safety, real-world effectiveness, or new uses.

4. Marketing application

For a conventional small-molecule drug, the sponsor submits a New Drug Application (NDA). For a biologic, the corresponding application is a Biologics License Application (BLA).

The application generally contains:

Full clinical study reports
Integrated summaries of safety and efficacy
Nonclinical data
CMC and manufacturing information
Proposed prescribing information and labeling
Risk-management proposals where needed
Plans for pharmacovigilance and post-marketing commitments

Reviewers evaluate whether benefits outweigh risks for the proposed indication and population. Manufacturing facilities are inspected to ensure compliance with current Good Manufacturing Practice (cGMP).

5. Labeling and approval

Approved labeling specifies:

Indication and patient population
Dose and administration
Contraindications
Warnings and precautions
Adverse reactions
Drug interactions
Use in pregnancy, lactation, children, and older adults
Pharmacogenomic information when clinically relevant

6. Post-marketing requirements

Approval does not end regulatory oversight. Sponsors must continue pharmacovigilance through:

Adverse-event reporting
Periodic safety reports
Product-quality reporting
Risk Evaluation and Mitigation Strategies (REMS) where required
Post-marketing studies or trials
Labeling changes when new safety information emerges
Regulatory submissions for manufacturing changes or new indications

The FDA also recognizes the role of valid pharmacogenomic data in IND, NDA, and BLA submissions, while exploratory data may sometimes be submitted voluntarily. See the FDA's pharmacogenomic data guidance.

8. Pharmacogenomic biomarkers and their use in clinical practice

A pharmacogenomic biomarker is a measurable DNA, RNA, chromosomal, protein, or other molecular characteristic that predicts a person's likely response to a medicine. In practice, many pharmacogenomic biomarkers are inherited germline gene variants, while cancer biomarkers are often acquired somatic tumor mutations.

Types of pharmacogenomic biomarkers

Metabolism biomarkers
Predict drug clearance or formation of active metabolites.
Examples: CYP2D6, CYP2C19, CYP2C9, TPMT, NUDT15, DPYD.
Transporter biomarkers
Predict transport into or out of tissues.
Example: SLCO1B1 and statin-related myopathy risk.
Drug-target biomarkers
Predict whether the intended target is present or responsive.
Examples: HER2 amplification, EGFR mutations, BCR-ABL fusion.
Immune-risk biomarkers
Identify risk of serious hypersensitivity or severe cutaneous reactions.
Examples: HLA-B57:01 and abacavir; HLA-B15:02 and carbamazepine.
Tumor predictive biomarkers
Help select anticancer therapy.
Examples: KRAS/NRAS status before some anti-EGFR therapies; BRAF V600 alterations for selected BRAF-targeted treatments.

Clinical uses

A. Selecting a drug

A biomarker can indicate that a drug is likely to work or should be avoided.

Example: in some cancers, treatment is selected only if the tumor has a particular actionable molecular alteration.

B. Selecting the dose

A genotype can identify reduced metabolism or increased toxicity risk.

Example: TPMT or NUDT15 testing supports thiopurine dose reduction or selection of an alternative therapy in susceptible patients.

C. Preventing severe adverse reactions

Example: HLA-B*57:01 testing is performed before abacavir. Patients with a positive result should not receive abacavir because of the risk of a potentially life-threatening hypersensitivity reaction.

D. Identifying patients needing monitoring or alternatives

Example: a CYP2C19 loss-of-function phenotype may reduce conversion of clopidogrel to its active metabolite. An alternative antiplatelet drug may be appropriate in specific high-risk settings, depending on the indication and guideline.

Appropriate clinical use

A pharmacogenomic result should be interpreted with:

The drug indication
The strength of evidence
Validated genotype-to-phenotype translation
Drug labeling
Professional guidelines, such as CPIC or DPWG guidance
Renal and hepatic function
Concomitant medicines
Patient-specific clinical factors

The FDA maintains a pharmacogenomic biomarker table, but inclusion in a drug label does not automatically mean testing is required in every patient. The label and applicable guidelines determine whether testing is mandatory, recommended, or informative.

9. How pharmacogenomic testing can optimize drug therapy

Pharmacogenomic testing can optimize therapy by using genetic information before or during prescribing to improve benefit and reduce harm.

Stepwise approach

Identify whether the drug has an actionable gene-drug association.
The association should be supported by a drug label or evidence-based guideline.
Order a validated test.
This may be a single-gene test, a targeted panel, or a tumor genomic panel in oncology.
Translate genotype into phenotype.
For example, CYP2D6 results may translate to poor, intermediate, normal, or ultrarapid metabolizer status.
Select the drug or dose.
Depending on the result, the clinician may:
- Use standard dosing
- Use a lower or higher dose
- Choose an alternative medicine
- Avoid a medicine entirely
- Increase monitoring
Continue clinical monitoring.
Genetics informs initial decisions but does not replace evaluation of response, toxicity, adherence, interactions, and organ function.

Examples

Clinical problem	Test result	Possible action
Risk of abacavir hypersensitivity	HLA-B*57:01 positive	Avoid abacavir
Thiopurine-induced myelosuppression	TPMT or NUDT15 reduced function	Use a major dose reduction or select an alternative, based on phenotype and guideline
Reduced clopidogrel activation	CYP2C19 intermediate or poor metabolizer	Consider an alternative P2Y12 inhibitor when clinically appropriate
Inadequate codeine analgesia or opioid toxicity risk	CYP2D6 poor or ultrarapid metabolizer	Select a non-CYP2D6-dependent analgesic where appropriate
Statin muscle toxicity risk	SLCO1B1 decreased function	Consider a lower-risk statin, altered dose, or enhanced monitoring
Severe fluoropyrimidine toxicity risk	DPYD reduced function	Reduce initial dose substantially or choose an alternative according to the relevant guideline

Benefits

Reduces avoidable serious adverse effects
Reduces trial-and-error prescribing
Improves likelihood of effective treatment
Supports rational dose selection
Can shorten time to an effective regimen
May reduce hospitalization and treatment costs in selected settings

Limitations

Not every drug has a useful pharmacogenomic test.
A negative result does not guarantee safety or efficacy.
Many variants are rare or may not be included in every testing panel.
Genotype does not fully account for kidney function, liver disease, age, diet, adherence, drug interactions, or disease severity.
Results must be interpreted using validated guidance rather than in isolation.

Recent systematic reviews indicate that implementation depends heavily on clinician education, suitable electronic clinical decision support, clear result interpretation, and integration into prescribing workflows. Relevant reviews include PMID 39136110 and PMID 42716951. These do not contradict the principles above, but they emphasize real-world implementation barriers.

10. Phase I reactions in drug metabolism, with examples

Phase I reactions are functionalization reactions that introduce or expose a functional group on a drug molecule. They generally increase polarity slightly and may prepare the drug for Phase II conjugation.

Phase I metabolism occurs mainly in the liver and often involves the cytochrome P450 system. It can produce inactive, active, or toxic metabolites.

Main Phase I reactions

Reaction	Description	Example
Oxidation	Addition of oxygen, removal of hydrogen, or oxidation of a functional group	Diazepam hydroxylation; phenytoin hydroxylation; codeine O-demethylation to morphine
Reduction	Gain of electrons or hydrogen, or reduction of functional groups	Chloramphenicol reduction; reduction of azo or nitro compounds by intestinal or hepatic enzymes
Hydrolysis	Cleavage of an ester or amide bond by water	Aspirin hydrolysis to salicylate; procaine hydrolysis; enalapril activation to enalaprilat
Dealkylation	Removal of an alkyl group, often an oxidative CYP-mediated reaction	Codeine O-demethylation to morphine; diazepam N-demethylation to desmethyldiazepam
Deamination	Removal of an amino group	Oxidative deamination of catecholamines by monoamine oxidase
Desulfuration/dehalogenation	Removal or replacement involving sulfur or halogen groups	Certain organophosphate compounds may undergo oxidative desulfuration to more active metabolites

A. Oxidation

Oxidation is the most common Phase I reaction. It is often catalyzed by CYP enzymes and can include:

Hydroxylation
N-, O-, or S-dealkylation
Deamination
Sulfoxidation
Epoxidation
Dehalogenation

Examples:

Codeine to morphine: O-demethylation by CYP2D6 produces the more active analgesic morphine.
Diazepam to desmethyldiazepam: N-demethylation, involving CYP enzymes, creates an active metabolite.
Warfarin metabolism: S-warfarin is metabolized predominantly by CYP2C9.
Acetaminophen to NAPQI: a small proportion is oxidized by CYP enzymes, including CYP2E1, producing a reactive metabolite.

B. Reduction

Reduction reactions are less common than oxidation. They can affect nitro, azo, carbonyl, and disulfide groups. Reductive metabolism may occur through microsomal enzymes, cytosolic enzymes, or intestinal microflora.

Examples:

Reduction of nitro or azo-containing compounds by intestinal bacteria.
Chloramphenicol can undergo nitroreduction to reactive intermediates.
Some corticosteroids and ketone-containing drugs can undergo carbonyl reduction.

C. Hydrolysis

Hydrolysis involves esterases, amidases, cholinesterases, or other hydrolases. Unlike many oxidative reactions, hydrolysis does not always depend on CYP enzymes.

Examples:

Aspirin is hydrolyzed to salicylate.
Procaine is hydrolyzed by plasma esterases.
Succinylcholine is hydrolyzed by plasma butyrylcholinesterase.
Enalapril, a prodrug, is hydrolyzed to active enalaprilat.
Oseltamivir, a prodrug, is hydrolyzed to active oseltamivir carboxylate.

Clinical significance of Phase I reactions

Phase I metabolism can:

Inactivate a parent drug
Activate a prodrug
Generate an active metabolite
Generate a toxic or reactive metabolite
Create a functional group for Phase II conjugation
Cause drug interactions through enzyme induction or inhibition
Produce genetically determined variation in drug response

Phase I products often undergo Phase II conjugation, such as glucuronidation, sulfation, acetylation, methylation, glutathione conjugation, or amino-acid conjugation. These conjugated metabolites are generally more water-soluble and are more readily excreted.

The major Phase I enzyme group is cytochrome P450, although other important enzymes include alcohol dehydrogenase, aldehyde dehydrogenase, monoamine oxidase, flavin-containing monooxygenase, esterases, and amidases. Lippincott Illustrated Reviews: Pharmacology, pp. 54-56.

This is a shared conversation. Sign in to Orris to start your own chat.